Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: The role of immunological synapses in understanding the cell biology of neuroimmune interactions

Current Gene Therapy

Volumn 7, Issue 5, 2007, Pages 347-360

  Lowenstein, Pedro R ^a   Mandel, Ronald J ^b   Xiong, Wei Dong ^a   Kroeger, Kurt ^a   Castro, Maria G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

CD8 T cells; Cervical lymph nodes; Dendritic cells; Immunoreactivity; Transgene expression

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; VIRUS VECTOR;

ADAPTIVE IMMUNITY; BRAIN CELL; BRAIN DISEASE; CLINICAL TRIAL; CYTOLOGY; CYTOTOXICITY; DENDRITIC CELL; DRUG SAFETY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VIVO STUDY; INNATE IMMUNITY; MEDICAL RESEARCH; NEUROANATOMY; NEUROIMMUNOLOGY; NICK END LABELING; NONHUMAN; PARKINSON DISEASE; REVIEW; SYNAPSE; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; VIRUS VIRULENCE;

ADENOVIRIDAE; ANIMALS; ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; BRAIN DISEASES; DEPENDOVIRUS; ENCEPHALITIS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; LENTIVIRUS; NEUROIMMUNOMODULATION; T-LYMPHOCYTES; TRANSGENES; VIRUSES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; LENTIVIRUS;

EID: 35348984094     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652307782151498     Document Type: Review

References (71)

1. Ali, S., G. D. King, J. F. Curtin, M. Candolfi, W. Xiong, C. Liu, M. Puntel, Q. Cheng, J. Prieto, A. Ribas, J. Kupiec-Weglinski, N. van Rooijen, H. Lassmann, P. R. Lowenstein and M. G. Castro (2005). Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res., 65(16): 7194-7204.
2. Barcia, C., C. Gerdes, W. Xiong, C. E. Thomas, C. Liu, K. M. Kroeger, M. G. Castro and P. R. Lowenstein (2006a). Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells may be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glial. Biology, 2(4): 309-327.
3. Barcia, C., C. E. Thomas, J. F. Curtin, G. D. King, K. Wawrowsky, M., Candolfi, W. D. Xiong, C. Liu, K. Kroeger, O. Boyer, J. Kupiec-Weglinski, D. Klatzmann, M. G. Castro and P. R. Lowenstein (2006b). In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J. Exp. Med., 203(9): 2095-2107.
4. Bechmann, I., I. Galea and V. H. Perry (2007). What is the blood-brain barrier (not)? Trends Immunol., 28(1): 5-11.
5. Blacklow, N. R., M. D. Hoggan and W. P. Rowe (1968). Serologic evidence for human infection with adenovirus-associated viruses. J. Natl. Cancer Inst., 40(2): 319-327.
6. Blacklow, N. R., M. D. Hoggan, M. S. Sereno, C. D. Brandt, H. W. Kim, R. H. Parrott and R. M. Chanock (1971). A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am. J. Epidemiol., 94(4): 359-366.
7. Cartmell, T., T. Southgate, G. S. Rees, M. G. Castro, P. R. Lowenstein and G. N. Luheshi (1999). Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. J. Neurosci., 19(4): 1517-1523.
8. Caux, C., S. Ait-Yahia, K. Chemin, O. de Bouteiller, M. C. Dieu-Nosjean, B. Homey, C. Massacrier, B. Vanbervliet, A. Zlotnik and A. Vicari (2000). Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin. Immunopathol., 22(4): 345-369.
9. Cemerski, S., J. Das, J. Locasale, P. Arnold, E. Giurisato, M. A. Markiewicz, D. Fremont, P. M. Allen, A. K. Chakraborty and A. S. Shaw (2007). The stimulatory potency of T cell antigens is influenced by the formation of the immunological synapse. Immunity, 26(3): 345-355.
10. Chiocca, E. A., K. M. Abbed, S. Tatter, D. N. Louis, F. H. Hochberg, F. Barker, J. Kracher, S. A. Grossman, J. D. Fisher, K. Carson, M. Rosenblum, T. Mikkelsen, J. Olson, J. M. Markert, S. Rosenfeld, L. B. Nabors, S. Brem, S. Phuphanich, S. Freeman, R. S. Kaplan and J. Zwiebel (2004). A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther., 10(5): 958-966.
11. Chirmule, N., K. Propert, S. Magosin, Qian, Y., R. Qian and J. Wilson (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther., 6(0969-7128): 1574-1583.
12. Cserr, H. F. and P. M. Knopf (1992). Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today, 13(12): 507-512.
13. Dewey, R. A., G. Morrissey, C. M. Cowsill, D. Stone, F. Bolognani, N. J. Dodd, T. D. Southgate, D. Klatzmann, H. Lassmann, M. G. Castro and P. R. Lowenstein (1999). Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat. Med., 5(11): 1256-1263.
14. Di Domenico, C., D. Di Napoli, Y. R. E. Gonzalez, A. Lombardo, L. Naldini and P. Di Natale (2006). Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum. Gene Ther., 17(11): 1112-1121.
15. During, M. J., M. G. Kaplitt, M. B. Stem and D. Eidelberg (2001). Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum. Gene Ther., 12(12): 1589-1591.
16. Dustin, M. L. and J. A. Cooper (2000). The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat. Immunol., 1(1): 23-29.
17. Eriksdotter Jonhagen, M., A. Nordberg, K. Amberla, L. Backman, T. Ebendal, B. Meyerson, L. Olson, Seiger, M. Shigeta, E. Theodorsson, M. Viitanen, B. Winblad and L. O. Wahlund (1998). Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 9(5): 246-257.
18. Erles, K., P. Sebokova and J. R. Schlehofer (1999). Update on the prevalence of serum antibodies (IgG and IgM) to adeno- associated virus (AAV). J. Med. Virol., 59(0146-6615): 406-411.
19. Favre, D., V. Blouin, N. Provost, R. Spisek, F. Porrot, D. Bohl, F. Marme, Y. Cherel, A. Salvetti, B. Hurtrel, J. M. Heard, Y. Riviere and P. Moullier (2002). Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol., 76(22): 11605-11611.
20. Friedl, P., A. T. den Boer and M. Gunzer (2005). Tuning immune responses: diversity and adaptation of the immunological synapse. Nat. Rev. Immunol., 5(7): 532-545.
21. Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen and M. L. Dustin (1999). The immunological synapse: a molecular machine controlling T cell activation. Science, 285(5425): 221-227.
22. Herzog, R. W. (2007). Immune responses to AAV capsid: are mice not humans after all? Mol. Ther., 15(4): 649-650.
23. Herzog, R. W., J. D. Mount, V. R. Arruda, K. A. High and C. D. Lothrop, Jr. (2001). Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol. Ther., 4(3): 192-200.
24. Huppa, J. B. and M. M. Davis (2003). T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol., 3(12): 973-983.
25. Huse, M., B. F. Lillemeier, M. S. Kuhns, D. S. Chen and M. M. Davis (2006). T cells use two directionally distinct pathways for cytokine secretion. Nat. Immunol., 7: 247-255.
26. Immonen, A., M. Vapalahti, K. Tyynela, H. Hurskainen, A. Sandmair, R. Vanninen, G. Langford, N. Murray and S. Yla-Herttuala (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther., 10(5): 967-972.
27. Kaplitt, M. G., A. Feigin, C. Tang, H. L. Fitzsimons, P. Mattis, P. A. Lawlor, R. J. Bland, D. Young, K. Strybing, D. Eidelberg and M. J. During (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet, 369(9579): 2097-2105.
28. Knopf, P. M., C. J. Harling-Berg, H. F. Cserr, D. Basu, E. J. Sirulnick, S. C. Nolan, J. T. Park, G. Keir, E. J. Thompson and W. F. Hickey (1998). Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J. Immunol., 161(2): 692-701.
29. Lee, K. H., A. D. Holdorf, M. L. Dustin, A. C. Chan, P. M. Allen and A. S. Shaw (2002). T cell receptor signaling precedes immunological synapse formation. Science, 295(5559): 1539-1542.
30. Lena, A. M., P. Giannetti, E. Sporeno, G. Ciliberto and R. Savino (2005). Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector. J. Gene Med., 7(8): 1086-1096.
31. Leon, B., M. Lopez-Bravo and C. Ardavin (2007). Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity, 26(4): 519-531.
32. Levi-Montalcini, R. (1987). The nerve growth factor 35 years later. Science 237(4819): 1154-1162.
33. Lo, W. D., G. Qu, T. J. Sferra, R. Clark, R. Chen and P. R. Johnson (1999). Adeno-associated virits-mediated gene transfer to the brain: duration and modulation of expression. Hum. Gene Ther., 10: 201-213.
34. Lowenstein, P. R. (2002). Dendritic cells and immune responses in the central nervous system. Trends Immunol., 23(2): 70.
35. Lowenstein, P. R. (2004). Input virion proteins: cryptic targets of antivector immune responses in preimmunized subjects. Mole. Ther., 9: 771-774.
36. Lowenstein, P. R. (2005). The case for immunosuppression in clinical gene transfer. Mol. Ther., 12(2): 185-186.
37. Maione, D., C. Della Rocca, P. Giannetti, R. D'Arrigo, L. Liberatoscioli, L. L. Franlin, V. Sandig, G. Ciliberto, N. La Monica and R. Savino (2001). An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc. Natl. Acad. Sci. USA, 98(11): 5986-5991.
38. Mandel, R. J. and C. Burger (2004). Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr. Opin. Mol. Ther., 6(5): 482-490.
39. Mandel, R. J., F. P. Manfredsson, K. D. Foust, A. Rising, S. Reimsnider, K. Nash and C. Burger (2006). Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol. Ther., 13(3): 463-483.
40. Mandel, R. J., K. G. Rendahl, S. K. Spratt, R. O. Snyder, L. K. Cohen and S. P. Leff (1998). Characterization of intrastriatal recombinant adeno-associated virus mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydroxylase I in a rat model of Parkinson's disease. J. Neurosci., 18: 4271-4284.
41. Mastakov, M. Y., K. Baer, C. W. Symes, C. B. Leichtlein, R. M. Kotin and M. J. During (2002). Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol., 76(16): 8446-8454.
42. Matyszak, M. K. (1998). Inflammation in the CNS: balance between immunological privilege and immune responses. Prog. Neurobiol., 56(1): 19-35.
43. Matyszak, M. K. and V. H. Perry (1996). The potential role of dendritic cells in irnmune-mediated inflammatory diseases in the central nervous system. Neuroscience, 74(2): 599-608.
44. McMahon, E. J., S. L. Bailey, C. V. Castenada, H. Waldner and S. D. Miller (2005). Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med., 11(3): 335-339.
45. McMenamin, P. G. (1999). Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J. Comp. Neurol., 405(4): 553-562.
46. McPhee, S. W., C. G. Janson, C. Li, R. J. Samulski, A. S. Camp, J. Francis, D. Shera, L. Lioutermann, M. Feely, A. Freese and P. Leone (2006). Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med., 8(5): 577-588.
47. Mian, A., M. Guenther, M. Finegold, P. Ng, J. Rodgers and B. Lee (2005). Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. Mol. Genet. Metab., 84(3): 278-288.
48. Mingozzi, F., N. C. Hasbrouck, E. Basner-Tschkarajan, S. A. Edmonson, D. J. Hui, D. E. Sabatino, S. Zhou, J. F. Wright, H. Jiang, G. F. Pierce, V. R. Arruda and K. A. High (2007). Modulation of tolerance to the transgene product in a non-human primate model of AAV-mediated gene transfer to liver. Blood.
49. Molnar-Kimber, K. L., D. H. Sterman, M. Chang, E. H. Kang, M. ElBash, M. Lanuti, A. Elshami, K. Gelfand, J. M. Wilson, L. R. Kaiser and S. M. Albelda (1998). Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther., 9(14): 2121-2133.
50. Monks, C. R., B. A. Freiberg, H. Kupfer, N. Sciaky and A. Kupfer (1998). Three-dimensional segregation of supramolecular activation clusters in T cells. Nature, 395(6697): 82-86.
51. Muramatsu, S., K. Fujimoto, K. Ikeguchi, N. Shizuma, K. Kawasaki, F. Ono, Y. Shen, L. Wang, H. Mizukami, A. Kume, M. Matsumura, I. Nagatsu, F. Urano, H. Ichinose, T. Nagatsu, K. Terao, I. Nakano and K. Ozawa (2002). Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther., 13(3): 345-354.
52. Muzyczka, N. and K. I. Berns (2001). Parvoiridae; The viruses and their replication In D. M. Knipe and P. M. Howley (eds). Fields Virology. Lippincott, Williams and Wilkins: 2327-2360.
53. O'Neal, W. K., H. Zhou, N. Morral, C. Langston, R. J. Parks, F. L. Graham, S. Kochanek and A. L. Beaudet (2000). Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol. Med., 6(3): 179-195.
54. Parks, R., C. Evelegh and F. Graham (1999). Use of helper-dependent adenoviral vectors of alternative serotypes, permits repeat vector administration. Gene Ther., 6(9): 1565-1573.
55. Pashenkov, M., N. Teleshova and H. Link (2003). Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol., 13(1): 23-33.
56. Peden, C. S., C. Burger, N. Muzyczka and R. J. Mandel (2004). Circulating anti-wt-AAV2 Antibodies Inhibit rAAV2-, but not rAAV5-mediated Gene Transfer in the Brain. J. Virol., 78: 6344-6359.
57. Reimsnider, S., F. P. Manfredsson, N. Muzyczka and R. J. Mandel (2007). Time Course of Transgene Expression After Intrastriatal Pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 Transduction in the Rat. Mol. Ther.
58. Sanftner, L. M., B. M. Suzuki, M. M. Doroudchi, L. Feng, A. McClelland, J. R. Forsayeth and J. Cunningham (2004). Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol. Ther., 9(3): 403-409.
59. Shi, Q., D. A. Wilcox, S. A. Fahs, H. Weiler, C. W. Wells, B. C. Cooley, D. Desai, P. A. Morateck, J. Gorski and R. R. Montgomery (2006). Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J. Clin. Invest., 116(7): 1974-1982.
60. Stevenson, P. G., S. Freeman, C. R. Bangham and S. Hawke (1997a). Virus dissemination through the brain parenchyma without immunologic control. J. Immunol., 159(4): 1876-1884.
61. Stevenson, P. G., S. Hawke, D. J. Sloan and C. R. Bangham (1997b). The immunogenicity of intracerebral virus infection depends on anatomical site. J. Virol., 71(1): 145-151.
62. Thomas, C. E., D. Birkett, I. Anozie, M. G. Castro and P. R. Lowenstein (2001a). Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol. Ther., 3(1): 36-46.
63. Thomas, C. E., G. Schiedner, S. Kochanek, M. G. Castro and P. R. Lowenstein (2000). Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc. Natl. Acad. Sci. USA, 97(13): 7482-7487.
64. Thomas, C. E., G. Schiedner, S. Kochanek, M. G. Castro and P. R. Lowenstein (2001b). Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum. Gene Ther., 12(7): 839-846.
65. Thomas, C. E., T. A. Storm, Z. Huang and M. A. Kay (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol., 78(6): 3110-3122.
66. Tuszynski, M. H., L. Thal, M. Pay, D. P. Salmon, H. S. U. R. Bakay, P. Patel, A. Blesch, H. L. Vahlsing, G. Ho, G. Tong, S. G. Potkin, J. Fallon, L. Hansen, E. J. Mufson, J. H. Kordower, C. Gall and J. Conner (2005). A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 11(5): 551-555.
67. Wong, L. F., L. Goodhead, C. Prat, K. A. Mitrophanous, S. M. Kingsman and N. D. Mazarakis (2006). Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum. Gene Ther., 17(1): 1-9.
68. Xiong, W., S., Goverdhana, S. A. Sciascia, M. Candolfi, I. M. Zirger, C. Barcia, J. F. Curtin, G. D. King, G. Jaita, C. Liu, K. Kroeger, H. Agadjanian, L. Medina-Kauwe, D. Palmer, P. Ng, P. R. Lowenstein and M. G. Castro (2006). Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J. Virol., 80(1): 27-37.
69. Xiong, W., M. Puntel, S. Mondkar, J. F. Curtin, M. Candolfi, K. M. Kroeger, C, Liu, D. Larocque, D. Palmer, P. Ng, P. R. Lowenstein and M. G. Castro (2007). Immune responses against tetracycline-dependant transactivators do not affect long-term transgene expression delivered by a helper-dependant adenoviral vector (HC-Ad). Mol. Ther., 15(Supplement 1): S96-S97.
70. Zaiss, A. K. and D. A. Muruve (2005). Immune responses to adeno-associated virus vectors. Curr. Gene Ther., 5(3): 323-331.
71. Zirger, J. M., C. Barcia, C. Liu, M. Puntel, N. Mitchell, I. Campbell, M. Castro and P. R. Lowenstein (2006). Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain. J. Virol., 80(11): 5655-5659.